| (19) |
 |
|
(11) |
EP 3 626 274 A3 |
| (12) |
EUROPEAN PATENT APPLICATION |
| (88) |
Date of publication A3: |
|
17.06.2020 Bulletin 2020/25 |
| (43) |
Date of publication A2: |
|
25.03.2020 Bulletin 2020/13 |
| (22) |
Date of filing: 15.04.2016 |
|
| (51) |
International Patent Classification (IPC):
|
|
| (84) |
Designated Contracting States: |
|
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL
NO PL PT RO RS SE SI SK SM TR |
| (30) |
Priority: |
16.04.2015 US 201562148696 P
06.08.2015 US 201562202133 P
01.09.2015 US 201562212634 P
|
| (62) |
Application number of the earlier application in accordance with Art. 76 EPC: |
|
16720253.0 / 3283126 |
| (71) |
Applicants: |
|
- Emory University
Atlanta, GA 30322 (US)
- Children's Healthcare of Atlanta, Inc.
Atlanta, GA 30329 (US)
|
|
| (72) |
Inventors: |
|
- DOERING, Christopher, B.
Atlanta, GA 30322 (US)
- SPENCER, Trent, H.
Atlanta, GA 30322 (US)
- BROWN, Harrison, C.
Atlanta, GA 30308 (US)
|
| (74) |
Representative: J A Kemp LLP |
|
14 South Square
Gray's Inn
London WC1R 5JJ
London WC1R 5JJ (GB) |
|
| |
|
| (54) |
RECOMBINANT PROMOTERS AND VECTORS FOR PROTEIN EXPRESSION IN LIVER AND USE THEREOF |
(57) Disclosed herein are recombinant viral vectors comprising a liver specific promotor
in operable combination with a heterologous nucleic acid sequence encoding a protein,
such as a clotting factor. Methods of treating a subject with a clotting disorder,
such as hemophilia A or hemophilia B, are also provided.